Attached files

file filename
10-K - FORM 10-K - CTI BIOPHARMA CORPd10k.htm
EX-12.1 - STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - CTI BIOPHARMA CORPdex121.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - CTI BIOPHARMA CORPdex211.htm
EX-10.23 - FORM OF EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT FOR EMPLOYEES - CTI BIOPHARMA CORPdex1023.htm
EX-10.22 - FORM OF EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT FOR DIRECTORS - CTI BIOPHARMA CORPdex1022.htm
EX-10.20 - REVISED DIRECTOR COMPENSATION POLICY - CTI BIOPHARMA CORPdex1020.htm
EX-32 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - CTI BIOPHARMA CORPdex32.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-160969, 333-161442, and 333-163479) and Form S-8 (Nos. 333-152168, 333-158260, and 333-162955) of Cell Therapeutics, Inc. of our reports dated February 26, 2010, relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which appear in this Form 10-K.

/s/ Stonefield Josephson, Inc.

San Francisco, California

February 26, 2010